

Please type a plus sign (+) inside this box --> SHENT & TR

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE are required to respond to a collection of information unites it displays a valid OMB control number.

Application, Number 10/40/2002.

Application Number 10/002,603 Filing Date October 30, 2001 COPL

| 27           |   |                      | 1 illing Date  | COLODE 00, 2001  |  |  |  |
|--------------|---|----------------------|--|--|--|--|--|
| 1            | FORM  |                      | First Named Inventor   | Alexander Gaiger  ORIG                                       |  |  |  |
|              | (To be used for all correspond  | ndence               | Group Art Unit   |  |  |  |  |
|              | after initial filing)   |                      | Examiner Name  |  |  |  |  |
|              |   |                      | Attorney Docket No.  | 210121.465C6   |  |  |  |
| -            |   | ENCLO                | SURES (check all that app                                      | oly)   |  |  |  |
| ]            | Fee Transmittal Form  | Тπ                   | Assignment Papers  | CD(s), Number  |  |  |  |
| Fee Attached |   |                      | (for an Application)   | of CD(s)   |  |  |  |
|              | Amendment/Response  |                      | Drawing(s)   | After Allowance  |  |  |  |
|              | After Final   |                      | Request for Corrected Filing                                   | Communication to Group                                       |  |  |  |
|              | Affidavits/declaration(s  | s)                   | Receipt  | Appeal Communication to                                      |  |  |  |
| ]            | Extension of Time Reques  |                      | Licensing-related Papers                                       | Board of Appeals and   |  |  |  |
| ]            | Express Abandonment   |                      | Petition   | Interferences  |  |  |  |
|              | Request   |                      | Petition to Convert to a<br>Provisional Application            | Appeal Communication to<br>Group (Appeal Notice, Brief,      |  |  |  |
| 3            | Information Disclosure<br>Statement: Form PTO-144   |                      | Power of Attorney,   | Reply Brief)   |  |  |  |
|              | (16 sheets)   |                      | Revocation, Change of  | Proprietary Information                                      |  |  |  |
| 3            | Cited References (2)  |                      | Correspondence Address   | Status Letter  |  |  |  |
| i            | Certified Copy of Priority  |                      | Declaration  | Return Receipt Postcard                                      |  |  |  |
| ,            | Document(s)   |                      | Statement under 37 CFR   | Additional Enclosure(s) (please identify below):             |  |  |  |
| ]            | Response to Missing Parts   | , 1-                 | 3.73(b)  |  |  |  |  |
|              | under 37 C.F.R. 1.52 or 1.  |                      | Terminal Disclaimer  |  |  |  |  |
| ]            | Response to Missing   |                      | Small Entity Statement   |  |  |  |  |
|              | Parts/Incomplete Application  | on 📗                 | Request for Refund   |  |  |  |  |
| e            | marks   |                      |  | <b></b>  |  |  |  |
|              |   |                      |  |  |  |  |  |
| _            |   |                      | APPLICANT, ATTORNEY,   | OR AGENT   |  |  |  |
| nd           | lividual Name   Jeffrey Hu  | indley, Pi           | h.D. 42,676  | 00500  |  |  |  |
|              |   |                      | 2  | PATENT TRADEMARK OFFICE                                      |  |  |  |
| Sic          | Inature   |                      |  |  |  |  |  |
| 21/2         |   |                      |  |  |  |  |  |
| Date 1/2/02  |   |                      |  | W. 1   |  |  |  |
| -            | <del>`</del>  | CE                   | RTIFICATE OF MAILING   |  |  |  |  |
| vit          | ereby certify that this corre<br>h sufficient postage as firs<br>ashington, D.C. 20231 on t | spondend<br>class ma | ce is being deposited with the<br>ail in an envelope addressed | e United States Postal Service to: Commissioner for Patents, |  |  |  |
|              |   | Monica S             |  |  |  |  |  |
| _            | anatura X   | 1                    | Chariles   | Date: 1/2 /  |  |  |  |
|              |   |                      |  |  |  |  |  |

| I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below. |                             |  |  |  |  |  |  |  |  |
|---|-----------------------------|--|--|--|--|--|--|--|--|
| Typed or printed name Monica Steinborn  |                             |  |  |  |  |  |  |  |  |
| Signature   | Maura Steinson Date: 1/3/02 |  |  |  |  |  |  |  |  |



ORIGINALL PROPERTY



### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE.

Applicants : Alexander Gaiger et al.

Application No. : 10/002,603

Filed : October 30, 2001

For : COMPOSITIONS AND METHODS FOR WT1 SPECIFIC

**IMMUNOTHERAPY** 

Docket No. : 210121.465C6

Commissioner for Patents Washington, DC 20231

#### INFORMATION DISCLOSURE STATEMENT

Sir

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449. This application is a continuation-in-part and relies, under 35 U.S.C. § 120, on the earlier filing date of prior application USAN 09/938,864, filed August 24, 2001; which is a continuation-in-part of USAN 09/785,019, filed February 15, 2001; which is a continuation-in-part of USAN 09/685,830, filed October 9, 2000; which is a continuation-in-part of USAN 09/684,361, filed October 6, 2000; which is a continuation-in-part of USAN 09/764,421, filed March 25, 1999; which is a continuation in part of USAN 09/164,223, filed September 30, 1998. The references listed on pages 1-13 of the attached Forms PTO-1449 were submitted to and/or cited by the Office in these prior applications and, therefore, are not required to be provided in the present application. If the Examiner wishes, copies will be provided upon request. However, the references listed on page 14 of Forms PTO-1449 were not submitted to and/or cited by the Office and are submitted herewith.

As to any reference made of record on the attached Form PTO-1449, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,
Seed Intellectual Property-Law Group PLLC

Jeffrey Hundley, Ph.D. Registration No. 42,676

JEH:mls 701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092 (206) 622-4900 Fax: (206) 682-6031

FORM PTO-1449 (REV.7-80)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. APPLICATION NO. 210121.465C6 10/002,603 APPLICANTS

| FORM PTO-14<br>(REV.7-80) | 49  | EEB / JULY 5                  | U.S. DEPARTMENT<br>PATENT AND TRAI | OF COMMERCE<br>DEMARK OFFICE | ATTY. DOCKET NO.<br>210121.465C6   |                            | APPLICATION NO.<br>10/002,603 |                  |                   |  |
|---------------------------|---|-------------------------------|------------------------------------|------------------------------|--|----------------------------|-------------------------------|------------------|-------------------|--|
| INI                       | ORM   | y took diseases               | JRE STATEM                         | ENT                          | APPLICANTS Alexander Gagier et al.   |                            |                               |                  |                   |  |
|                           |   | (Use several sheets if n      | ecessary)                          |                              | FILING DATE<br>October 30, 2001  | Gi                         | ROUP ART UNIT                 |                  | Oo, Oe al         |  |
|                           |   |                               | U.S                                | PATENT                       | DOCUMENTS  |                            |                               |                  | 1                 |  |
| EXAMINER<br>INITIAL       |   | DOCUMENT NUMBER               | DATE                               |                              | NAME   | CLASS                      | SUBCLASS                      | FILIN<br>IF APPR | G DATE<br>OPRIATE |  |
|                           | AA  | 5,350,840                     | 09/27/94                           | Call et al.                  |  | 536                        | 23.1                          |                  |                   |  |
|                           |   |                               | FORE                               | GN PATEN                     | T DOCUMENTS  |                            |                               |                  | j                 |  |
|                           | T   | DOCUMENT<br>NUMBER            | DATE                               |                              | COUNTRY  |                            |                               | TRANS            | LATION NO         |  |
|                           | AB  | WO99/58135                    | 11/18/99                           | PCT                          |  |                            |                               | 1123             | INC.              |  |
|                           | AC  | WO95/29995                    | 11/09/95                           | PCT                          |  |                            |                               |                  |                   |  |
|                           | AD  | WO95/06725                    | 03/09/95                           | PCT                          |  |                            |                               |                  |                   |  |
|                           | AE  | WO 91/07509                   | 05/30/91                           | PCT                          |  |                            |                               |                  |                   |  |
|                           |   | отні                          | ER PRIOR A                         | RT (Including                | Author, Title, Date, Pertinent   | Pages Ftc )                |                               |                  |                   |  |
|                           | AF  | Aaronson an<br>transformation | d Todaro, "I<br>on susceptibi      | Developmen<br>lity to SV4    | at of 3t3-like lines fro<br>0," J. Cell. Physiol.                                  | om Balb/c :<br>72(2):141-1 | mouse embr<br>148, Octobe     | yo cul<br>r 1968 | tures:            |  |
|                           | AG  | Adachi et al.<br>(WT1)," Onc  | , "Midkine a<br>cogene 13: 2       | s a novel ta<br>197-2203, 1  | rget gene for the Wi<br>996.   | lms' tumor                 | suppressor                    | gene             |                   |  |
|                           | AH  | Algar et al., in myeloid le   | "A WT1 anti<br>eukaemia cel        | sense oligo<br>l lines," On  | nucleotide inhibits proliferation and induces apoptosis ogene 12: 1005-1014, 1996. |                            |                               |                  |                   |  |
|                           | AI  | Armstrong e<br>mammalian      | t al., "The ex<br>embryo," Me      | pression of<br>chanisms o    | the Wilms' tumour f Development 40: 8  | gene, WT1<br>5-97, 1992    | , in the deve                 | eloping          | -                 |  |
|                           | AJ  | specific for V<br>1999.       | VILMS Tum                          | or Antigen-                  | ation of leukemic pro<br>1 (WT-1)," Blood, 9                                       | 94(10):532                 | A-533A, No                    | vembe            | r 15,             |  |
|                           | AK  | Leukemias A<br>1997.          | re Associate                       | d With a W                   | lms' Tumor Gene (v<br>orse Long-Term Ou  | tcome," Bl                 | ood 90(3): 1                  | 217-12           | 225,              |  |
|                           | AL  | Bergmann et<br>Leukemia an    | al., "Wilms<br>d Lymphoma          | Tumor Gen<br>25: 435-44      | e Expression in Acu<br>3, 1997.  | te Myeloid                 | Leukemias                     | ,,,              |                   |  |
|                           | Brenner et al., "RNA polymerase chain reaction detects different levels of four alternatively spliced WTI transcripts in Wilms' tumors," Oncogene 7: 1431-1433, 1992. |                               |                                    |                              |  |                            |                               |                  |                   |  |
| XAMINI                    | ER  |                               |                                    |                              | DATE CONSIDEREI  | )                          |                               |                  | _                 |  |
|                           |   |                               |                                    |                              |  |                            |                               |                  |                   |  |

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-144 U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. APPLICATION NO. ORIGINALL FIRST (REV.7-80) PATENT AND TRADEMARK OFFICE 210121.465C6 10/002,603 APPLICANTS TION DISCLOSURE STATEMENT Alexander Gagier et al. al sheets if necessary) FILING DATE GROUP ART UNIT October 30, 2001

#### U.S. PATENT DOCUMENTS

| *EXAMINER<br>INITIAL |    | DOCUMENT NUMBER    | DATE         | NAME  | CLASS            | SUBCLASS    |              | OPRIATI |
|----------------------|----|--------------------|--------------|---|------------------|-------------|--------------|---------|
|                      | ВА |                    |              |   |                  |             |              |         |
|                      |    |                    | FOREIG       | ON PATENT DOCUMENTS   |                  |             |              |         |
|                      |    | DOCUMENT<br>NUMBER | DATE         | COUNTR  | Y                |             | TRANS<br>YES | LATIO   |
|                      | ВВ |                    |              |   |                  |             |              |         |
|                      |    | OTHE               | R PRIOR AI   | RT (Including Author, Title, Date, Pertine                            | ent Pages, Etc.) |             |              |         |
|                      | вс |                    |              | ssion of the Wilms' Tumor C<br>ukemic Blast Cells," Leukem            |                  |             |              | emia    |
|                      | BD |                    | l may provid | ' tumor gene is frequently ex<br>le a marker for residual blast<br>5. |                  |             |              | ıls of  |
|                      | BE |                    |              | Characterization, and Express<br>ey Development," <i>Molecular</i>    |                  |             |              |         |
|                      | BF |                    |              | Characterization of a Zinc Fir<br>Fumor Locus," Cell 60: 509-:        |                  | ide Gene at | the H        | umai    |
|                      | BG |                    | requent in C | negative mutations of the W<br>ML blast crisis and de novo            |                  |             |              |         |
|                      | ВН |                    | enal tumour  | of the Wilms' tumour gene<br>s: an immunohistochemical s              |                  |             |              |         |
|                      | ВІ |                    |              | stochemical detection of the cell tumour," Histopathology             |                  |             | 'l in        |         |

**EXAMINER** 

вј

BK

and virus production in a group of murine virus-induced leukemia cell lines," The Journal DATE CONSIDERED

Chesebro et al., "Characterization of Ia8 antigen, THY-1.2 antigen, complemnt receptors,

Chen et al., "T-cells for tumor therapy can be obtained from antigen-loaded sponge

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

of Immunology 117(4):1267-1274, October 1976.

implants," Cancer Research 54(4):1065-1070, February 15, 1994.

Sheet 3 of 14 CONTORRES ORIGINALI STREET FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. APPLICATION NO. (REV 7-80) PATENT AND TRADEMARK OFFICE 210121.465C6 10/002,603 APPLICANTS INFORMATION DISPLOSURE STATEMENT Alexander Gagier et al. al sheets if necessary) FILING DATE GROUP ART UNIT October 30, 2001 U.S. PATENT DOCUMENTS EXAMINER FILING DATE DOCUMENT NUMBER DATE NAME CLASS SUBCLASS INITIAL IF APPROPRIATE CA FOREIGN PATENT DOCUMENTS DOCUMENT TRANSLATION DATE COUNTRY NUMBER CB OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) De Bruijn et al., "Peptide loading of empty major histocompatibility complex molecules on CC RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses," Eur J Immunol 21(12):2963-2970, December 1991, Deavin et al., "Statistical comparison of established T-cell eptiope predictors against a large CD database of human and murine antigens," Molecular Immunology, 33(2):145-155, 1996. Drummond et al., "Repression of the Insulin-Like Growth Factor Gene by the Wilms CE Tumor Suppressor WT1," Science 257: 674-677, 1992. Feller and de la Cruz, "Tsites (Version 1.1) A computer program to determine T cell CF epitopes using four predictive algorithms." Nature 349: 720-721, 1991. Foster et al., "Characterization of prostatic epithelial cell lines derived from transgenic CG

| 3330, August 15, 1997.
| CH | Frazier et al., "Expression of the Tumor Suppressor Gene WT1 in Both Human and Mouse Bone Marrow," Blood 86: 4704-4706, 1995 (letter).

| CI | Gaiger et al., "WT1: A new leukemia and cancer antigen A," Proceedings of the Annual Meeting of the American Association for Cancer Research, 40:424, 1999.

Gaiger et al., "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," *Blood 96*(4):1480-1489, August 15, 2000.

Gaiger et al., "Immunity to WT1 in animal models and leukemia pateints." Blood.

EXAMINER

CI

DATE CONSIDERED

adenocarcinoma of the mouse prostate (TRAMP) model," Cancer Research 57(16):3325-

EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

94(10):78. November 15, 1999.

|                            |     | OILE                       | _                      |  |  | _         |       |              | neet 4   | of <u>14</u> |
|----------------------------|-----|----------------------------|------------------------|--|--|-----------|-------|--------------|----------|--------------|
| FORM PTO-144<br>(REV.7-80) | , [ |                            | S. DEPARTMENT O        |  | ATTY. DOCKET NO.<br>210121.465C6                   |           |       | 1002,603     |          |              |
| INF                        | OR  |                            | RE STATEM              | ENT  | APPLICANTS Alexander Gagier et                     | al        |       |              | ~°°      |              |
|                            | (   | The Abenne Seets if ne     |                        |  | FILING DATE October 30, 2001  GROUP ART UNIT       |           |       | UP ART UNIT  | NG/A     | Val. Par     |
|                            |     |                            | ***                    | D + MN 100 1                                       |  |           |       |              | /        | - Tri        |
| *EXAMINER<br>INITIAL       |     | DOCUMENT NUMBER            | DATE DATE              | PATENT   | NAME NAME  | CLA       | ss    | SUBCLASS     | FILING   | DATE         |
|                            | DA  |                            |                        |  |  |           |       |              |          |              |
|                            |     |                            | FOREIG                 | CNDATES  | T DOCUMENTS  |           |       |              |          |              |
|                            | _   | DOCUMENT                   |                        | GNPATE   |  |           |       |              | TRANS    | LATION       |
|                            |     | NUMBER                     | DATE                   |  | COUNTRY  |           |       |              | YES      | NO           |
|                            | ĎВ  |                            |                        |  |  |           |       |              |          |              |
|                            |     | OTHE                       | R PRIOR A              | RT (Including                                      | Author, Title, Date, Pertinent Pa                  | ges. Etc. | )     |              |          |              |
|                            | DC  |                            | ith, "Long t           | erm culture  | e of tumour-specific cy                            |           |       | cells," Nati | ire      |              |
|                            | DD  |                            |                        | e transplantation of syn<br>ncer Research 28(3):43 |  |           |       | ey, and      | i        |              |
|                            | DE  |                            |                        |  | etinoic acid receptor-a<br>ogene 10: 1125-1129,    |           | by th | e Wilms' t   | umor     |              |
|                            | DF  |                            | 4 in transfor          |  | in the Wilms tumor ge<br>primary kidney cells,"    |           |       |              |          |              |
|                            | DG  |                            | 'Alternative           |  | nd genomic structure of -9622, 1991.               | f the V   | Vilm  | s tumor ge   | ne WT    | 1,"          |
|                            | DH  |                            |                        |  | vithin an 11p13 Zinc F<br>ell 61: 1257-1269, 199   |           | Gene  | e Contribut  | es to tl | ne           |
|                            | DI  |                            |                        |  | ng sites for the Wilms'<br>): 277-284, 1995.       | tumo      | ur su | ippressor p  | rotein   |              |
|                            | DJ  | Product of the 21271-21275 | e Wilms' Tu<br>, 1993. | mor Locus  | ony-stimulating Factor-<br>," The Journal Of Biol  | ogica     | l Che | emistry 268  | 8(28):   |              |
|                            | DK  |                            | e Wilms' Tu            |  | ony-stimulating Factor-<br>i," The Journal Of Biol |           |       |              |          |              |
| EXAMINI                    | ER  |                            |                        |  | DATE CONSIDERED                                    |           |       |              |          |              |
|                            |     |                            |                        |  |  |           |       |              |          |              |

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

APPLICATION NO. 10/002,603-00 FORM PTO-1449 (REV.7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO. 210121.465C6 INFORMATION DISCOSSIVE STATEMENT APPLICANTS Alexander Gagier et al. FILING DATE October 30, 2001

|                     | EA FOREIGN PATENT DOCUMENTS |  |   |  |              |              |            |      |  |  |  |
|---------------------|-----------------------------|--|---|--|--------------|--------------|------------|------|--|--|--|
|                     |                             |  | U.S.  | PATENT DOCUMENTS   |              |              |            | /    |  |  |  |
| EXAMINER<br>INITIAL |                             | DOCUMENT NUMBER  | DATE  | NAME   | CLASS        | SUBCLASS     |            |      |  |  |  |
|                     | EA                          |  |   |  |              |              |            |      |  |  |  |
| -                   |                             |  | FOREI   | GN PATENT DOCUMENTS  |              |              |            |      |  |  |  |
|                     | Γ                           |  |   |  |              |              | TRANSLATIO |      |  |  |  |
|                     |                             | NUMBER   | DATE  | COUNTRY  |              |              | YES        | NO   |  |  |  |
|                     | EB                          |  |   |  |              |              |            |      |  |  |  |
|                     |                             | OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) |   |  |              |              |            |      |  |  |  |
|                     | EC                          |  |   |  | culture," E  | xperimenta   | l Cell     |      |  |  |  |
|                     | ED                          |  | Huang et al., "Tissue, Developmental, and Tumor-Specific Expression of Divergent Transcripts in Wilms Tumor," Science 250: 991-994, 1990. |  |              |              |            |      |  |  |  |
|                     | EE                          |  | Inoue et al., "Aberrant Overexpression of the Wilms Tumor Gene (WT1) in Human Leukemia," <i>Blood</i> 89(4): 1405-1412, 1997.             |  |              |              |            |      |  |  |  |
|                     | EF                          |  |   | Follow-Up of Minimal Residua<br>Tumor Gene) Expression Leve        |              |              |            |      |  |  |  |
|                     | EG                          |  |   | nor Gene (WT1) Competes Wittor Cells," <i>Blood 91</i> (8): 2969-2 |              | ation-Induc  | ing Si     | gnal |  |  |  |
|                     | ЕН                          |  |   | ew Prognostic Factor and a Nev<br>e in Acute Leukemia," Blood 8    |              |              | ion of     |      |  |  |  |
|                     | EI                          |  |   | tchard-Jones, "Wilms' Tumor (<br>Leukemia and May Confer Dr        |              |              |            | 2961 |  |  |  |
|                     | EJ                          |  |   | Mutations in the Wilms' Tumo                                       | r Gene WT1   | in Leuken    | nias," I   | Bloo |  |  |  |
|                     | EK                          | Kreidberg et a   | al., "WT-1 I  | s Required for Early Kidney De                                     | evelopment,' | ' Cell 74: 6 | 79-691     | l,   |  |  |  |

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

| FORM PTO-14-<br>(REV.7-80) | MAI   |   | J.S. DEPARTMENT<br>ATENT AND TRAD |                              |                  | DOCKET NO.<br>121.465C6                 |                   |                | LICATION NO.<br>/002,603  |                   |                 |
|----------------------------|-------|---|-----------------------------------|------------------------------|------------------|---|-------------------|----------------|---------------------------|-------------------|-----------------|
|                            | oky   | <b>эдох из</b> сьози                            | RE STATEM                         | IENT                         |                  | kander Gagier et                        | al.               |                | OAI                       | GINGLY V          |                 |
|                            |       | Ose several sheets if ne                        | :cessary)                         |                              |                  | DATE<br>ober 30, 2001                   |                   | GRO            | DUP ART UNIT              | 72/2              | FILEDS          |
|                            |       |   | U.S                               | . PATENT I                   | DOCU             | JMENTS                                  |                   |                |                           | _                 | \               |
| *EXAMINER<br>INITIAL       |       | DOCUMENT NUMBER                                 | DATE                              |                              | NA               | ME                                      | CLA               | ASS            | SUBCLASS                  | FILING<br>IF APPR | DATE<br>OPRIATE |
|                            | FA    |   | L                                 |                              |                  |   |                   |                |                           |                   |                 |
|                            |       |   | FORE                              | IGN PATEN                    | NT DO            | CUMENTS                                 |                   |                |                           |                   |                 |
|                            |       | DOCUMENT<br>NUMBER                              | DATE                              |                              |                  | COUNTRY                                 |                   |                |                           | TRANS:<br>YES     | NO              |
|                            | FB    |   |                                   |                              |                  |   |                   |                |                           |                   |                 |
|                            |       | ОТНЕ  | R PRIOR A                         | RT (Including                | Author,          | Title, Date, Pertinent Pe               | ages, Etc.        | <del></del> -  |                           |                   |                 |
|                            | FC    | Kudoh et al.,<br>embryonal ca<br>Oncogene 13    | arcinoma cel                      | lls induces a                | on of the        | he Wilms tumor<br>tic cell death in     | r suppr<br>respor | esso<br>ise to | r gene WT<br>o retinoic a | l in F9<br>cid,"  | )               |
|                            | FD    | Kudoh et al.,                                   | "G <sub>1</sub> phase a           | arrest induce                | ed by \ Acad     | Wilms tumor pro<br>l. Sci. USA 92: 4    | otein V           | VT1<br>521,    | is abrogate<br>1995.      | d by              |                 |
|                            | FE    | Kwok and Hi<br>1989.                            | guchi, "Avo                       | oiding false                 | positi           | ves with PCR,"                          | Nature            | 2 339          | 7:237-238,                | May 1             | 8,              |
|                            | FF    | Larsson et al.<br>Domains Is R                  | , "Subnuclea<br>legulated by      | ar Localizat<br>Alternative  | ion of<br>Splic  | WT1 in Splicing," Cell 81: 3            | ng or T<br>91-401 | rans           | cription Fa               | ctor              |                 |
|                            | FG    | Ljunggren et a<br>480, August 2                 | al., "Empty<br>2, 1990.           | MHC class                    | I mole           | ecules come out                         | in the            | cold           | l," Nature .              | 346:47            | 6-              |
|                            | FH    | Lozzio and Lo<br>Philadelphia                   | ozzio, "Hum<br>chromosome         | nan chronic<br>e," Blood 45  | myelo<br>5(3):32 | ogenous leukemi<br>21-334, March 1      | ia cell-<br>1975. | line           | with positi               | ve                |                 |
|                            | Fi    | Luo et al., "Tl<br>Oncogene 11:                 | he tumor sup<br>: 743-750, 1      | ppressor ger<br>995.         | ne WT            | Γ1 inhibits ras-n                       | nediate           | d tra          | ınsformatic               | on,"              |                 |
|                            | FJ    | Madden et al.<br>Product," Scie                 | , "Transcrip<br>ence 253: 15      | tional Repre<br>550-1552, 19 | ession<br>991.   | Mediated by the                         | e WT1             | Wil            | ims Tumor                 | Gene              |                 |
|                            | FK    | Maurer et al.,<br>downregulater<br>25: 945-950, | d early in the                    | s' tumor ger<br>e course of  | ne is e          | expressed in a su<br>entiation in vitro | ibset of          | f CD<br>erim   | 34 progeni<br>ental Hem   | tors an           | d<br>y          |
| EXAMINE                    | R     |   |                                   |                              | DATE             | CONSIDERED                              |                   |                |                           |                   |                 |
| * EXAMINE                  | ER: I | nitial if reference considere                   | d whether or not                  | criteria is in conf          | formance         | with MPED 600 December                  | . I'm ab          |                |                           |                   |                 |

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not ir conformance and not considered. Include copy of this form with next communication to applicant(s).

|                            |            | 010                            |                                |               |   |              | :                     | Sheet <u>7</u>     | of <u>14</u>    |
|----------------------------|------------|--------------------------------|--------------------------------|---------------|---|--------------|-----------------------|--------------------|-----------------|
| FORM PTO-144<br>(REV.7-80) | E FL       |                                | S. DEPARTMENT<br>TENT AND TRAD |               | ATTY, DOCKET NO.<br>210121.465C6              | APP.<br>10.  | 002,603               | COPYO              |                 |
| INF                        | \Z<br>ORM( | COUCHIO!                       | RE STATEM                      | IENT          | APPLICANTS Alexander Gagier e                 | t al.        | LICATION NO. (002,603 | "VAL               | YFILE           |
|                            |            | (Use several sheets if ne      | cessary)                       |               | FILING DATE GROUP ART UNIT October 30, 2001   |              |                       |                    |                 |
|                            |            |                                | U.S                            | . PATENT      | DOCUMENTS                                     |              |                       |                    |                 |
| *EXAMINER<br>INITIAL       |            | DOCUMENT NUMBER                | DATE                           |               | NAME  | CLASS        | SUBCLASS              | FILING<br>IF APPRO | DATE<br>OPRIATE |
|                            | GA         |                                |                                |               |   |              |                       | L                  |                 |
|                            |            |                                | FORE                           | IGN PATEN     | T DOCUMENTS                                   |              |                       |                    |                 |
|                            |            | DOCUMENT<br>NUMBER             | DATE                           |               | COUNTRY                                       |              |                       | TRANS              | NO              |
|                            | GB         |                                |                                |               |   |              |                       |                    |                 |
|                            |            | ОТНЕ                           | R PRIOR A                      | RT (Including | Author, Title, Date, Pertinent                | Pages, Etc.) |                       |                    |                 |
|                            | GC         |                                |                                |               | ce variants have oppo<br>kidney cells," Oncog |              |                       |                    | icity           |
|                            | GD         |                                |                                |               | clonal Antibodies Of<br>ute Leukemia," Int. J |              |                       |                    |                 |
|                            | GE         |                                |                                |               | tumor gene (wt1) tra<br>te leukemias," Leuke  |              |                       |                    | r               |
|                            | GF         |                                | Ouring Fetal                   |               | e Expression in Hum<br>ent and Early Clonog   |              |                       |                    | 486-            |
|                            | GG         | Miwa et al., Leukemia 6(       |                                |               | ms' Tumor Gene (W)                            | Γ1) in Hum   | an Leukem             | ias,"              |                 |
|                            | GH         | Miyagi et al.,<br>Leukemia Ce  |                                |               | ndidate Wilms' Tumo<br>0-977, 1993.           | or Gene, W   | 71, in Hum            | ian                |                 |
|                            | GI         | Morris et al.,<br>tumor locus, |                                |               | e zinc finger protein<br>48, 1991.            | encoded by   | the WT1               | Wilms'             |                 |

EXAMINER

GJ

GK

DATE CONSIDERED

Murata et al., "The Wilms tumor suppressor gene WT1 induces G1 arrest and apoptosis in

Mundlos et al., "Nuclear localization of the protein encoded by the Wilms' tumor gene

WT1 in embryonic and adult tissues," Development 119: 1329-1341, 1993.

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

myeloblastic leukemia M1 cells," FEBS Letters 409: 41-45, 1997.



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 210121.465C6 APPLICANTS

APPLICATION NO. 10/002,603 CO. PROPERTY OF PROPERTY OF

DISCLOSURE STATEMENT

(Use several sheets if necessary)

Alexander Gagier et al. FILING DATE October 30, 2001

|                      |    |                 | 0.5.1 | ATENI DOCUMENTS |       |          |                               |
|----------------------|----|-----------------|-------|-----------------|-------|----------|-------------------------------|
| *EXAMINER<br>INITIAL |    | DOCUMENT NUMBER | DATE  | NAME            | CLASS | SUBCLASS | FILING DATE<br>IF APPROPRIATE |
|                      | НА |                 |       |                 |       |          |                               |
|                      |    |                 |       |                 |       |          | <del></del>                   |

## FOREIGN PATENT DOCUMENTS

|    | DOCUMENT | DATE | COLINTRY | TRANS | LATION |   |
|----|----------|------|----------|-------|--------|---|
|    | NUMBER   | 2    | COUNTRY  | YES   | NO     | ı |
| нв |          |      |          |       |        | ı |

|        | OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)   |
|--------|--|
| нс     | Nakagama et al., "Sequence and Structural Requirements for High-Affinity DNA Binding by the WT1 Gene Product," <i>Molecular and Cellular Biology 15</i> (3): 1489-1498, 1995.  |
| HD     | Nichols et al., "WT1 Induces Expression of Insulin-like Growth Factor 2 in Wilms' Tumor Cells," Cancer Research 55: 4540-4543, 1995.   |
| HE     | Ogawa et al., "Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogeneic bone marrow transplantation: importance of the monitoring of minimal residual disease by WT1 assay," Bone Marrow Transplantation 21: 525-527, 1998. |
| HF     | Old et al., "Antigenic properties of chemically induced tumors," Annals of the New York Academy of Sciences 101:80-107, November 20, 1962.   |
| <br>HG | Osaka et al., "WT1 Contributes To Leukemogenesis: Expression Patterns In 7,12-<br>Dimethylbenz[a]Anthracene (DMBA)-Induced Leukemia," <i>International Journal of Cancer</i> 72: 696-699, 1997.  |
| нн     | Parker et al., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," <i>Journal of Immunology 152</i> : 163-175, 1994.  |
| н      | Patek et al., "Transformed cell lines susceptible or resistant to in vivo surveillance against tumorigenesis," <i>Nature 276</i> :510-511, November 30, 1978.  |
| нл     | Patmasiriwat et al., "Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities," <i>Leukemia 10</i> : 1127-1133, 1996.  |
| нк     | Pelletier et al., "Expression of the Wilms' tumor gene WT1 in the murine urogenital system," Genes & Development 5: 1345-1356, 1991.   |

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-144 P INFORMATION DISCLOSURE STATEMENT

Ів

(Use several sheets if necessary)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO. 210121.465C6 APPLICATION NO. 10/002,603

APPLICANTS Alexander Gagier et al. FILING DATE

GROUP ART UNIT

OF COR. THE STREET October 30, 2001 U.S. PATENT DOCUMENTS

| *EXAMINER<br>INITIAL     |    | DOCUMENT NUMBER | DATE | NAME    | CLASS | SUBCLASS | FILING DATE<br>IF APPROPRIATE |  |  |  |  |  |
|--------------------------|----|-----------------|------|---------|-------|----------|-------------------------------|--|--|--|--|--|
|                          | IA |                 |      |         |       |          |                               |  |  |  |  |  |
| FOREIGN PATENT DOCUMENTS |    |                 |      |         |       |          |                               |  |  |  |  |  |
|                          |    | DOCUMENT        | DATE | COUNTRY |       |          | TRANSLATION                   |  |  |  |  |  |

DOCUMENT NUMBER DATE COUNTRY

|            | В  |  |  |  |  |  |  |  |  |  |  |  |
|------------|----|--|--|--|--|--|--|--|--|--|--|--|
|            |    | OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)   |  |  |  |  |  |  |  |  |  |  |
|            | iC | Pelletier et al., "Germline Mutations in the Wilms' Tumor Suppressor Gene Are Associated with Abnormal Urogenital Development in Denys-Drash Syndrome," <i>Cell</i> 67: 437-447, 1991.                                   |  |  |  |  |  |  |  |  |  |  |
|            | ID | Phelan et al., "Wilms' Tumor Gene, WTI, mRNA Is Down-regulated during Induction of Erythroid and Megakaryocytic Differentiation of K562 Cells," Cell Growth & Differentiation 5: 677-686, 1994.                          |  |  |  |  |  |  |  |  |  |  |
|            | IE | Pogue et al., "Amino-terminal alteration of the HLA-A 0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity," Proc. Natl. Acad. Sci. USA 92: 8166-8170, 1995. |  |  |  |  |  |  |  |  |  |  |
|            | IF | Pritchard-Jones et al., "The candidate Wilms' tumour gene is involved in genitourinary development," <i>Nature 346</i> : 194-197, 1990.  |  |  |  |  |  |  |  |  |  |  |
|            | IG | Pritchard-Jones et al., "The Wilms tumour (WT1) gene is mutated in a secondary leukaemia in a WAGR patient," <i>Human Molecular Genetics</i> 3(9): 1633-1637, 1994.  |  |  |  |  |  |  |  |  |  |  |
|            | IH | Rackley et al., "Expression of the Wilms' Tumor Suppressor Gene WT1 during Mouse Embryogenesis," Cell Growth & Differentiation 4: 1023-1031, 1993.   |  |  |  |  |  |  |  |  |  |  |
|            | II | Ramani and Cowell, "The Expression Pattern Of Wilms' Tumour Gene (WT1) Product In Normal Tissues And Paediatric Renal Tumours," Journal Of Pathology 179: 162-168, 1996.   |  |  |  |  |  |  |  |  |  |  |
|            | וו | Rauscher et al., "Binding of the Wilms' Tumor Locus Zinc Finger Protein to the EGR-1 Consensus Sequence," Science 250: 1259-1262, 1990.  |  |  |  |  |  |  |  |  |  |  |
|            | IK | Rauscher, "The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor," FASEB J. 7: 896-903, 1993.  |  |  |  |  |  |  |  |  |  |  |
| DALABOR ID |    |  |  |  |  |  |  |  |  |  |  |  |

**EXAMINER** 

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s)

FORM PTO-1449 (REV.7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION MELOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO. 210121.465C6

October 30, 2001

APPLICATION NO. 10/002,603

APPLICANTS
Alexander Gagier et al.
FILING DATE

GROUP ART UNIT

U.S. PATENT DOCUMENTS

| U.S. PATENT DOCUMENTS |    |                 |      |      |       |          |                               |  |  |  |  |
|-----------------------|----|-----------------|------|------|-------|----------|-------------------------------|--|--|--|--|
| *EXAMINER<br>INITIAL  |    | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE<br>IF APPROPRIATE |  |  |  |  |
|                       | JA |                 |      |      |       |          |                               |  |  |  |  |
|                       |    |                 |      |      |       |          |                               |  |  |  |  |

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER DATE COUNTRY TRANSLATION YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

|    | OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)  |
|----|---|
| JC | Rauscher et al., "Characterization of monoclonal antibodies directed to the amino-terminus of the WT1, Wilms' tumor suppressor," <i>Hybridoma</i> , 17(2):191-198, April 1998.                |
| JD | Reddy et al., "WT1-mediated Transcriptional Activation Is Inhibited by Dominant<br>Negative Mutant Proteins," <i>The Journal Of Biological Chemistry</i> 270(18): 10878-10884,<br>1995.       |
| JE | Rothbard and Taylor, "A sequence pattern common to T cell epitopes," <i>EMBO Journal</i> , 7(1):93-100, 1988.   |
| JF | Rupprecht et al., "The Wilms' Tumor Suppressor Gene WT1 Is Negatively Autoregulated,"<br>The Journal Of Biological Chemistry 269(8): 6198-6206, 1994.   |
| JG | Sadovnikova et al., "Generation of human tumor-reactive cytotoxic T-cells against peptides presented by non-self HLA class I molecules," <i>Eur.J. Immunol.</i> , 28:193-200, 1998.           |
| JH | Schmid et al., "Prognostic significance of WT1 gene expression at diagnosis in adult <i>de novo</i> acute myeloid leukemia," <i>Leukemia 11</i> : 639-643, 1997.                              |
| ונ | Sekiya et al., "Downregulation of Wilms' Tumor Gene (wt1) During Myelomonocytic Differentiation in HL60 Cells," <i>Blood 83</i> (7): 1876-1882, 1994.   |
| 11 | Sharma et al., "Molecular Cloning of Rat Wilms' Tumor Complementary DNA and a Study of Messenger RNA Expression in the Urogenital System and the Brain," Cancer Research 52: 6407-6412, 1992. |
| JK | Silberstein et al., "Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer," <i>Proc. Natl. Acad. Sci. USA 94</i> : 8132-8137, 1997.                               |

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)

SU.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 210121.465C6 APPLICATION NO. 10/002,603

APPLICANTS Alexander Gagier et al.

(Use several sheets if necessary)

INFORMATION DISCLOSURE STATEMENT

FILING DATE October 30, 2001

GROUP ART UNIT

#### U.S. PATENT DOCUMENTS

| *EXAMINER<br>INITIAL |    | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE<br>IF APPROPRIATE |
|----------------------|----|-----------------|------|------|-------|----------|-------------------------------|
| К                    | ΚA |                 |      |      |       |          |                               |

# FOREIGN PATENT DOCUMENTS

DOCUMENT DATE COUNTRY NUMBER NO KВ

|          |    | OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)  |
|----------|----|---|
| К        | кс | Skeiky et al., "Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis," <i>Infection and Immunity</i> 67(8):3998-4007, August 1999. |
| К        | CD | Slavin and Strober, "Spontaneous murine B-cell leukaemia," <i>Nature 272:</i> 624-626, April 13, 1978.  |
| к        | Œ  | Svedberg et al., "Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program," <i>Oncogene 15</i> : 1-8, 1997.                           |
| к        | CF | Tadokoro et al., "Genomic Organization of the Human WT1 Gene," <i>Jpn. J. Cancer Res.</i> 83: 1198-1203, 1992.  |
| К        | (G | Tadokoro et al., "Intragenic homozygous deletion of the WTI gene in Wilms' tumor," Oncogene 7: 1215-1221, 1992.   |
| k        | СН | Tadokoro et al., "PCR Detection of 9 Polymorphisms in the WT1 Gene," <i>Human Molecular Genetics 2</i> (12): 2205-2206, 1993.   |
| K        | a  | Tadokoro et al., "Taql RFLPs at the Wilms' tumor gene (WT1)," <i>Nucleic Acids Research</i> 19(9): 2514, 1991.  |
| k        | a  | Telerman et al., "Identification of the cellular protein encoded by the human Wilms' tumor (WTI) gene," Oncogene 7: 2545-2548, 1992.  |
| k        | ΚK | Toes et al., "Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts," <i>Int. J. Cancer</i> , 66:686-691, 1996.   |
| EVANDIED |    | DATE CONSIDERED   |

**EXAMINER** 

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT (REV.7-80)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY, DOCKET NO. 210121.465C6 APPLICATION SEPARATE PROPERTY OF THE PROPERTY

(Use several sheets if necessary)

APPLICANTS Alexander Gagier et al. FILING DATE October 30, 2001

#### ILS. PATENT DOCUMENTS

|                      | CISTATE DOCUMENTS |                 |      |      |       |          |                               |  |  |  |
|----------------------|-------------------|-----------------|------|------|-------|----------|-------------------------------|--|--|--|
| *EXAMINER<br>INITIAL |                   | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE<br>IF APPROPRIATE |  |  |  |
|                      | МА                |                 |      |      |       |          |                               |  |  |  |
|                      |                   |                 |      |      |       |          |                               |  |  |  |

## FOREIGN PATENT DOCUMENTS

|  |  |        | DOCUMENT |         | COUNTRY | TRANSLATION |  |  |
|--|--|--------|----------|---------|---------|-------------|--|--|
|  |  | NUMBER | DATE     | COUNTRY | YES     | NO          |  |  |
|  |  | мв     |          |         |         |             |  |  |

|    | OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)   |
|----|--|
| мс | Tsurutani et al., "cDNA cloning and developmental expression of the porcine homologue of WT1," Gene 211(2): 215-220, 1998.   |
| MD | Wang et al., "A second transcriptionally active DNA-binding site for the Wilms tumor gene product, WT1," <i>Proc. Natl. Acad. Sci. USA 90</i> : 8896-8900, 1993.   |
| ме | Wang et al., "The Wilms' Tumor Gene Product WT1 Activates or Suppresses Transcription through Separate Functional Domains," <i>The Journal Of Biological Chemistry</i> 268(13): 9172-9175, 1993.   |
| MF | Wang et al., "The Wilms' Tumor Gene Product, WT1, Represses Transcription of the Platelet-derived Growth Factor A-chain Gene," <i>The Journal Of Biological Chemistry</i> 267(31): 21999-22002, 1992.  |
| MG | Wang et al., "WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein," <i>Oncogene 10</i> (6): 1243-1247, 1995.   |
| мн | Watson et al., "Leukemia viruses associated with mouse myeloma cells," <i>Proceeding of the National Academy of Sciences 66</i> (2):344-351, June 1970.  |
| мі | Werner et al., "Inhibition of Cellular Proliferation by the Wilms' Tumor Suppressor WT1 Is Associated with Suppression of Insulin-Like Growth Factor I Receptor Gene Expression," <i>Molecular and Cellular Biology</i> 15: 3516-3522, 1995. |
| мл | Wu et al., "GATA-1 Transactivates the WT1 Hematopoietic Specific Enhancer," The Journal Of Biological Chemistry 270(11): 5944-5949, 1995.  |
| мк | Yamagami et al., "Growth Inhibition of Human Leukemic Cells by WT1 (Wilms Tumor Gene) Antisene Oligodeoxynucleotides: Implications for the Involvement of WT1 in Leukemogenesis," <i>Blood 87</i> (7): 2878-2884, 1996.                      |
|    |  |

EXAMINER

DATE CONSIDERED

\*EXAMINER:

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

| FORM PTO-1449<br>(REV.7-80) |      |                          | J.S. DEPARTMENT<br>ATENT AND TRAD  |                  | 210121.465C6   | 10         | /002,603°/         | VOR PA                        |  |  |
|-----------------------------|------|--------------------------|--|------------------|--|------------|--------------------|-------------------------------|--|--|
| INF                         | ORM. | ATION DISCLOSU           | RE STATEM  | ENT              | E ATTY DOCKET NO.  APPLICATION |            |                    |                               |  |  |
|                             |      | (Use several sheets if n | ecessary)  |                  | FILING DATE October 30, 2001   | GR         | DUP ART UNIT       |                               |  |  |
|                             |      |                          | U.S.   | PATENT I         | DOCUMENTS  |            |                    |                               |  |  |
| *EXAMINER<br>INITIAL        |      | DOCUMENT NUMBER          | DATE   |                  | NAME   | CLASS      | SUBCLASS           | FILING DATE<br>IF APPROPRIATE |  |  |
|                             | NA   |                          |  |                  |  |            |                    |                               |  |  |
|                             |      |                          | FORE   | GN PATEN         | T DOCUMENTS  |            |                    |                               |  |  |
|                             |      | DOCUMENT<br>NUMBER       | DATE   |                  | COUNTRY  |            |                    | TRANSLATION YES NO            |  |  |
|                             | NB   |                          |  |                  |  |            |                    |                               |  |  |
|                             |      | ОТН                      | ER PRIOR A   | RT (Including    | Author, Title, Date, Pertinent Pa  | ges, Etc.) |                    |                               |  |  |
|                             | NC   |                          | Ye et al., "Regulation of WT1 by phosphorylation: inhibition of DNA binding, a transcriptional activity and cellular translocation," <i>The EMBO Journal</i> 15(20): 5 |                  |  |            |                    |                               |  |  |
|                             | ДZ   |                          |  |                  |  |            |                    |                               |  |  |
|                             | NE   |                          |  |                  |  |            |                    |                               |  |  |
|                             | NF   |                          |  |                  |  |            |                    |                               |  |  |
|                             | NG   |                          |  |                  |  |            |                    |                               |  |  |
|                             | NH   |                          |  |                  |  |            |                    |                               |  |  |
|                             | NI   |                          |  |                  |  |            |                    |                               |  |  |
|                             | NJ   |                          |  |                  |  |            |                    |                               |  |  |
|                             | NK   |                          |  |                  |  |            |                    |                               |  |  |
| EXAMINE                     | ER   |                          |  |                  | DATE CONSIDERED  |            |                    |                               |  |  |
| *EXAMI                      |      |                          |  |                  | ria is in conformance with MPEP<br>vith next communication to applic   |            | ne through citatie | n if not in                   |  |  |
|                             |      | manee and not cons       | include te   | PJ STAINS WITH W | to applic  |            |                    |                               |  |  |

|   | - 1  |                    | <b>5</b> 1 | -              |             |                                    | _     |             |             |         |          |  |
|---|--|--------------------|------------|----------------|-------------|------------------------------------|-------|-------------|-------------|---------|----------|--|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE |  |                    |            |                |             |                                    |       |             |             |         |          |  |
| INEC  | DM/  | ATION DISCL        | OSI        | DF STATEM      | ENT         | APPLICANTS Alexander Gagier et al. |       |             |             |         |          |  |
| INT   |  | (Use several shee  |            | 2.11           | FILING DATE | 41.                                | GRO   | UP ART UNIT | <u></u>     | WENT TO |          |  |
|   |  |                    |            |                |             | October 30, 2001                   |       |             |             |         | <u> </u> |  |
|   |  |                    |            | U.S.           | PATENT 1    | DOCUMENTS                          |       |             |             |         | `        |  |
| *EXAMINER<br>INITIAL  |  | DOCUMENT NUM       | BER        | DATE           |             | NAME                               | CLA   | SS          | SUBCLASS    |         | OPRIATE  |  |
|   | OA   | 844                |            |                |             |                                    | L     |             |             |         |          |  |
|   |  |                    |            | FOREI          | GN PATEN    | T DOCUMENTS                        |       |             |             |         |          |  |
|   |  | DOCUMENT<br>NUMBER | Г          | DATE           |             | COUNTRY                            |       |             |             | TRANS   | LATION   |  |
|   | ОВ   |                    |            |                |             |                                    |       |             |             |         |          |  |
|   | OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) |                    |            |                |             |                                    |       |             |             |         |          |  |
|   | ос   |                    |            |                |             | of antigen-specific T ly           |       |             | s," Science | 274:9   | 4-96,    |  |
|   | 00   | October            | 4, 1       | 996.           |             |                                    |       |             |             |         |          |  |
|   | OD   |                    |            |                |             | n-specific T cells with            |       |             | nt soluble  | class I | [        |  |
|   | OD   | MHC co             | vale       | ent peptide co | omplexes,"  | Immunity 8:675-682, J              | une 1 | 998.        |             |         |          |  |
|   | OE   |                    |            |                |             |                                    |       |             |             |         |          |  |
|   |  |                    |            |                |             |                                    |       |             |             |         |          |  |
|   | OF   |                    |            |                |             |                                    |       |             |             |         |          |  |
|   |  |                    |            |                |             |                                    |       |             |             |         |          |  |
|   | OG   |                    |            |                |             |                                    |       |             |             |         |          |  |
|   |  |                    |            |                |             |                                    |       |             |             |         |          |  |
|   | он   |                    |            |                |             |                                    |       |             |             |         |          |  |
|   |  |                    |            |                |             |                                    |       |             |             |         |          |  |
|   | оі   |                    |            |                |             |                                    |       |             |             |         |          |  |
|   |  |                    |            |                |             |                                    |       |             |             |         |          |  |
|   | OJ   |                    |            |                |             |                                    |       |             |             |         |          |  |
|   |  |                    |            |                |             |                                    |       |             |             |         |          |  |
|   | ок   |                    |            |                |             |                                    |       |             |             |         |          |  |
|   |  |                    |            |                |             |                                    |       |             |             |         |          |  |
| EXAMINE   | R  |                    |            |                |             | DATE CONSIDERED                    |       |             |             |         |          |  |

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant(s).

\*EXAMINER: